Power Law company profile

Praxis Precision Medicines

Biotech & Life Sciences · Cambridge, United States · Founded 2015 · IPO 2020 Unicorn

Developing therapies for central nervous system disorders based on genetic insights into neuronal imbalance

Valuation

$8.28B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

13 investors on Praxis Precision Medicines's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 13 investors entered at this stage

Point72 Ventures

Cormorant Asset Management

Irving Investors

Verition Fund Management

Vida Ventures

Eventide Asset Management

Avoro Capital Advisors

Citadel

OCV Partners

Blackstone

Qatar Investment Authority

Adage Capital

Novo Holdings

Global footprint

Where Praxis Precision Medicines has talent and traffic

Workforce by country

🇺🇸 United States · Cambridge HQ

Book a demo for the full country breakdown

Web traffic by country

12K monthly visits
across markets

🇺🇸 United States65%

🏳️ Korea15.8%

🏳️ Republic of8.3%

🇮🇳 India4.2%

🇪🇸 Spain3.3%

Top 5 markets shown

Market sentiment

What the market is saying about Praxis Precision Medicines

An AI-synthesized read of the highest-engagement posts about Praxis Precision Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Praxis Precision Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles